Hemophilia and Other Severe Bleeding DisordersNCT02512250
Swiss Hemophilia Registry
An observational study of Hemophilia and Other Severe Bleeding Disorders, run by Swiss Hemophilia Network at 19 sites in Switzerland.
Trial summary
The Swiss Hemophilia Registry will collect data on the prophylactic and therapeutic use of factor concentrates in patients with hemophilia and other severe bleeding disorders in Switzerland. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Hemophilia and Other Severe Bleeding Disorders
- What is being tested?
- Registry
- How many people
- 900 participants
- Where
- 19 sitesSwitzerland
- Study dates
- May 2015to Dec 2025
- How long will I take part?
- 10 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients with hemophilia and other severe bleeding disorders
Who may be able to join
- Diagnosis of hemophilia or other severe bleeding disorders. Signed inform consent
Who cannot join
- None
Trial locations and contacts
19 sites in 1 country.
19 sites in 1 country
Switzerland19 sites, 19 recruiting
- Recruiting
Kantonsspital Aarau Zentrum für Onkologie/Hämatologie und Transfusionsmedizin
Aarau, 5001
Marc Heizmann, MD, 062 838 60 50, marc.heizman@ksa.ch
- Recruiting
Kinderklinik
Aarau, 5001
MD
- Recruiting
Universitätsspital Basel Diagnostische Hämatologie
Basel, 4031
Maria Martinez, MD, maria.martinez@usb.ch
- Recruiting
Universitätskinderspital beider Basel (UKBB) Abteilung Onkologie/Hämatologie
Basel, 4056
Nicolas von der Weid, MD, 061 704 12 12, Nicolas.VonderWeid@ukbb.ch
- Recruiting
Ospedale San Giovanni
Bellinzona, 6500
Pierluigi Brazzola, MD, 091 811 89 76, pierluigi.brazzola@eoc.ch
- Recruiting
Servizio di Ematologia Ospedale Regionale di Bellinzona e Valli
Bellinzona, 6500
Bernhard Gerber, MD, 091 811 87 78, bernhard.gerber@eoc.ch
- Recruiting
Inselspital, Universitätsspital Bern Poliklinik für Hämatologie
Bern, 3010
Johanna Kremer, MD, 031 632 90 22, johanna.kremer@insel.ch
- Recruiting
Kantonspital Graubünden
Chur, 7000
Reta Malär, MD, + 41 81 256 60 41, reta.malaer@sgr.ch
- Recruiting
Unité d'Hémostase HUG
Geneva, 1211
Francoise Boehlen, MD, 022 372 97 57, francoise.boehlen@hcuge.ch
- Recruiting
Unité d'Oncologie-Hématologie pédiatrique, Hôpital des Enfants HUG
Geneva, 1211
Gabriele Martin, MD, 022 372 47 12, gabriele.martin@hcuge.ch
- Recruiting
Centre Hospitalier Universitaire Vaudois Service d'Hématologie
Lausanne, 1011
Lorenzo Alberio, MD, 021 314 11 11, lorenzo.alberio@chuv.ch
- Recruiting
Policlinique d'onco-hématologie péd., CHUV
Lausanne, 1011
Mattia Rizzi, MD, mattia.rizzi@chuv.ch
- Recruiting
Kantonsspital Luzern Abteilung Hämatologie
Lucerne, 6000
Pascal Raddatz, MD, 041 205 14 39, pascale.raddatz@luks.ch
- Recruiting
Kinderspital Luzern
Lucerne, 6000
Freimut Schilling, MD, 041 205 11 11, freimut.schilling@luks.ch
- Recruiting
Ostschweizer Kinderspital St. Gallen
Sankt Gallen, 9006
Heinz Hengartner, MD, 071 243 14 36, heinz.hengartner@kispisg.ch
- Recruiting
Kantonspital St. Gallen
Sankt Gallen, 9007
Lukas Graf, MD, lukas.graf@zlmsg.ch
- Not yet recruiting
Kinder und Erwachsenenzentrum Sion Service Régional Valaisan de Transfusion Sanguine CRS
Sion, 1950
Pierre-Yves Lovey, MD, 027 603 48 63, pyves.lovey@hopitalvs.ch
- Recruiting
University Children's Hospital
Zurich, 8032
Manuela Albisetti, MD, + 41 44 266 71 38, manuela.albisetti@kispi.uzh.ch
- Recruiting
University Hospital Zürich
Zurich, 8090
Alice Trinchero, MD, .+41 44 255 11 11, alice.trinchero@usz.ch
About this study
The Swiss Hemophilia Registry will collect data on the prophylactic and therapeutic use of factor concentrates in patients with hemophilia and other severe bleeding disorders in Switzerland.
- Being tested
- Registry
- Medical subject headings
- Hemophilia A
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RegistryOther
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of incidence of disease and inhibitor development
Demographics, Comorbidties, factor consumption for prophylaxis, bleeding and surgery, inhibito develeopment
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jul 2015 (estimated)
- Study startMay 2015
- Primary completionDec 2025 (estimated)
- Study completionDec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hemophilia and Other Severe Bleeding DisordersStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 900 participants (estimated)
- Target duration
- 10 Years
Sponsor and investigators
- Lead sponsor
- Swiss Hemophilia Network
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02512250
- Sponsor's protocol ID
- 2014-0667
- Status last verified
- Oct 2022
- First submitted
- 26 Jul 2015
- Last updated
- 27 Oct 2022
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Oct 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Swiss Hemophilia Registry
- ClinicalTrials.gov ID
- NCT02512250
- Acronym / sponsor ID
- 2014-0667
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 900 participants (estimated)
- Lead sponsor
- Swiss Hemophilia NetworkUniversity, hospital or other
- Study start
- May 2015
- Primary completion
- Dec 2025 (estimated)
- Study completion
- Dec 2025 (estimated)
- First posted
- 30 Jul 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Swiss Hemophilia Registry will collect data on the prophylactic and therapeutic use of factor concentrates in patients with hemophilia and other severe bleeding disorders in Switzerland.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 10 Years
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients with hemophilia and other severe bleeding disorders
Key inclusion criteria (1 listed)
- Diagnosis of hemophilia or other severe bleeding disorders. Signed inform consent
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Registry | Other | – |
Primary outcome
Number of incidence of disease and inhibitor development
Time frame: 1 year
Demographics, Comorbidties, factor consumption for prophylaxis, bleeding and surgery, inhibito develeopment
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Oct 2022.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
19 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hemophilia and Other Severe Bleeding Disorders, run by Swiss Hemophilia Network at 19 sites in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 27 Oct 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 19 sites in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Manuela Albisetti, MD (+41 44 266 71 38, manuela.albisetti@kispi.uzh.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of incidence of disease and inhibitor development (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Oct 2022.